
    
      This is a randomized, double-blind, placebo-controlled, multicenter study. The study will
      consist of 3 phases: a screening phase, a treatment phase, and a follow-up phase.

      Approximately 60 participants with active Rheumatoid Arthritis will be randomly assigned to
      receive placebo, 50mg ABX464 or 100mg ABX464 during the treatment phase.

      The maximum period of active treatment will be 12 weeks. The maximum duration of study
      participation will be 17 weeks.

      Participant safety will be monitored throughout the study. In addition, several experimental
      and clinical endpoints will be assessed to obtain information on preliminary efficacy.
    
  